The use of technetium-99m radiolabeled human antimicrobial peptides for infection specific imaging.
Bacterial resistance to conventional antibiotics poses a challenge medicine to search for alternatives. Cationic antimicrobial peptides (AMPs) are promising for the development of a new class of antibiotics. This review focuses on the use of technetium-99m labeled synthetic AMPs, derived from human natural cationic AMPs, for target-delivery to and in vivo detection of infection sites caused by (drug-resistant) micro-organisms. The scintigraphic approach has proven to be a reliable method for evaluating AMPs in pharmacological studies and for optimizing target-delivery of radiolabeled AMPs to pathological sites in animals and humans. In addition, the effect of alterations in amphipathicity, amino acid substitution, and dimerization on the biological performance of AMPs is reported. Radiolabeled AMPs offer good perspectives for diagnosis of infections, for monitoring therapy, and, most importantly, for the ability to discriminate between infections and sterile inflammatory processes.
Brouwer
C P J M
CP
Department of Radiology, section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Sarda-Mantel
L
L
Meulemans
A
A
Le Guludec
D
D
Welling
M M
MM
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D023181:Antimicrobial Cationic Peptides; D001424:Bacterial Infections / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D006801:Humans; D015609:Organotechnetium Compounds / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013667:Technetium
D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; D015609:Organotechnetium Compounds; D010446:Peptide Fragments; D019275:Radiopharmaceuticals; C485080:technetium 99m ubiquicidin(29-41); D013667:Technetium